Introduction
The effectiveness of methadone maintenance treatment in reducing heroin use, criminal activity, risk of HIV, fatal and non-fatal heroin overdoses, and in improv- one to precipitate withdrawal [8] . A particular method using an opiate receptor antagonist for opiate detoxification is the so-called ultra-rapid opiate detoxification, which is usually performed under conditions of general anesthesia [9, 10] or profound sedation [11, 12] . Different modifications of the techniques have been developed and introduced into practice [13, 14] . One major drawback to these methods is the need of expensive critical care. Furthermore, safety is also a major issue for these procedures, since cases of death have been reported following this procedure [15] .
Furthermore, many of the anesthesia procedures used in heroin-dependent patients have been found to have higher complication rates in methadone patients [16] . Moreover methadone patients seem to experience more severe withdrawal symptoms, which may be due to the lipophilicity, large distribution volume and long half-life of methadone. These particularities often make it necessary to modify and complicate the detoxification procedure [16] .
The majority of trials studying opiate detoxification treatments, and especially those examining rapid methods, did not specifically select for methadone-substituted patients, while many patients included were withdrawing from methadone [4, 12, [17] [18] [19] . Furthermore, several studies describing methadone detoxification used methadone mainly to stabilize the opiate dose prior to withdrawal and not as substitution treatment [9, 20, 21] .
With regard to antagonist-assisted detoxification, the antagonist has usually been maintained over the detoxification period [10, 11, 22, 23] , and there is no documented clinical experience on the temporary administration of antagonists to accelerate the withdrawal process without continuing the administration of the antagonist. However, the administration of small doses of antagonists may be an interesting approach not only to accelerate withdrawal but possibly also to modify the symptom spectrum, and even to reduce symptom intensity as suggested by recent reports [18, 22] .
The present study was aimed to assess the efficacy and tolerability of a 3-day detoxification procedure accelerated with a unique dose of naltrexone in a selected sample of methadone-substituted patients for whom the indication of an urgent detoxification was given.
Methods

Setting
The study was carried out at the Psychiatric Hospital of the Canton Neuchâtel, Perreux, Switzerland, which covers a catchment area of 200,000 inhabitants. As a rule drug-dependent patients are admitted on a voluntary basis.
The usual method for methadone discontinuation in the canton of Neuchâtel consists of slow downtitration over several weeks on an outpatient basis. For many patients, a several-week program in abstinence-centered therapeutic communities is often recommended by treating professionals following the withdrawal of methadone. However, one admission criterion of these centers is abstinence already at entry into the program, and places are often only available at short term. Hence there is a necessity for a rapid, simple and short treatment protocol for these patients as a means of methadone discontinuation allowing them to enter the therapeutic community within a few days.
Treatment Protocol
The treatment protocol outlined in table 1 was developed by shortening the usual clinical protocol by adding a single dose of naltrexone. All medication was administered orally.
The last methadone dose was administered the morning of the admission day before admission itself in all patients. Patients entered the unit between 10: 00 and 11: 00 a.m. During the whole 1st day of hospitalization no pharmacological treatment was applied. On the 2nd day of hospitalization, the treatments were administered as indicated in table 1 . On the 3rd day no further drugs were administered.
Participants
Methadone patients who were interested in withdrawal from methadone maintenance treatment were considered for the study. In order to be included in the protocol, patients had to be at least 18 years old, give informed consent, be under methadone substitution for at least 12 months, and without concomitant illegal drug consumption for at least 6 months as established by regular urine drug screenings. Furthermore, the decision to discontinue methadone had to be made jointly by the patient, his treating physician as well as the responsible physician of the detoxification unit, on the basis of a pre-hospitalization interview which took place 2-4 weeks before hospitalization, and during which social, professional and familial stability was evaluated.
The main non-inclusion criteria were serious medical or psychiatric conditions, pregnancy, and known intolerances to the substances used in the present protocol. Finally, patients who were also dependent on benzodiazepines, alcohol or cocaine according to ICD-10 were excluded. Patients in whom urine screening revealed recent benzodiazepine use, but for whom no benzodiazepine dependence could be diagnosed, were included.
Assessment
All patients underwent medical assessment on admission and a urine drug screening was done in order to assess potential other drug consumptions. Furthermore, standard laboratory measurements (full blood count, clinical chemistry profile) were performed, and results were available before application of the first dose of treatment. Patients with samples positive for opiates (other than methadone) were excluded from the study. Diagnoses were determined according to ICD-10.
The Objective Opiate Withdrawal Scale (OOWS) [24] was applied on the 2nd, 3rd and 4th day of hospitalization, twice a day, at 8: 00 a.m. and at 6: 00 p.m. Blood pressure and pulse rate were also measured. The OOWS is an objective scale with 13 observable physical signs of withdrawal. A clinician rates the symptoms as being absent (0) or present (1) . The maximum score is therefore 13.
In addition the following three items were attached to the standard OOWS scale: craving, insomnia, and lack of appetite.
Blood pressure, heart frequency and temperature were assessed twice daily (8: 00 a.m. and 6: 00 p.m.). As all values remained within normal ranges during the whole observation period, they will not be specifically reported in the results section.
Follow-Up
A follow-up was performed by telephone interview 1 week and 6 months after discharge. As all patients were transferred to a therapeutic community after methadone detoxification, a nurse from the corresponding therapeutic community was contacted after 1 week to assess possible persistent withdrawal symptoms. A further telephone interview at 6 months after withdrawal was done which aimed to investigate retention in treatment, relapse in drug abuse, and possible reintroduction of methadone.
Results
Characterization of the Patients
The patient sample consisted of 3 women and 7 men. The mean age was 30.0 8 3.7 (range 25-35) years. Besides the ICD-10 diagnosis of opiate dependence and methadone substitution, 3 patients were also diagnosed as having borderline personality disorder (ICD-10: F60.31), 1 patient had a diagnosis of impulsive personality disorder (ICD-10: F60.30), and 1 patient had a history of obsessivecompulsive disorder (ICD-10: F42.2) and generalized anxiety disorder (ICD-10: F41.1).
Two patients were treated on admission to the hospital with quetiapine, and 1 patient received paroxetine. The mean methadone dose at entry was 44.5 8 38.4 (range 10-140) mg/day.
The initial urine drug screening revealed recent amphetamine consumption in 1 patient, benzodiazepine intake in 5 patients, cannabis consumption in 5 patients, and 1 subject had recently consumed cocaine.
Efficacy
The efficacy data are shown in table 2 . The symptoms are arranged in 4 groups (A-D) according to their evolution over the 3 days of observation. As only 1 patient presented with mydriasis during the whole observation period, serious doubts about the accuracy of the ratings for this item must be raised, and therefore it is not shown in table 2 .
Group A symptoms, which contains some of the most typical signs of the opiate withdrawal syndrome (craving, hot and cold flashes, piloerection and anxiety), are characterized by a high initial prevalence with most of the patients presenting with these symptoms which continuously disappear over the following 3 days.
Group B symptoms are mainly related to neurovegetative hyperactivation and are characterized by a high initial prevalence and rapid disappearance in most patients.
Group C symptoms are also linked to neurovegetative phenomena, however their prevalence remains low over the whole observation period.
Group D symptoms, such as muscle twitches, insomnia and lack of appetite, reappeared in some patients at the end of day 2 and the beginning of day 3. Four of the 5 patients who complained of muscle twitches and pain on the morning of day 3 were among the patients who presented insomnia the nights before.
Follow-Up
One week after dismissal from the unit, i.e. 10 days after the beginning of treatment, the responsible nurse of the therapeutic community was contacted by telephone and interviewed with regard to possible persistent withdrawal symptoms. Among the 10 patients, 5 presented further episodes of aches and 6 had 1 or more nights with sleep problems (initial or midnight insomnia). No evident other withdrawal symptoms were reported. Craving seemed to be absent in all patients during the 1st week after dismissal from our unit, as reported by the nurse.
With regard to the follow-up at 6 months, 8 of 10 patients completed the therapeutic program as planned or were still in the therapeutic community. Of these 8 patients, 2 had had at least one consumption episode, 1 patient abusing alcohol and 1 patient relapsing to heroin. Of the 2 patients who did not complete the therapeutic program, 1 patient of foreign nationality was expelled from Switzerland and therefore the program was interrupted, and the other patient dropped out due to a relapse to cannabis and alcohol consumption. This last patient has subsequently received buprenorphine substitution treatment.
Discussion
In this pilot study on 10 patients undergoing rapid methadone detoxification using a single dose of naltrexone, we found the present treatment procedure to shorten and satisfactorily control the withdrawal syndrome. The typical signs of opiate withdrawal, craving, hot and cold flashes, piloerection and anxiety, improved continuously over the 3 days of observation.
The course of the symptoms can be interpreted as biphasic. A first withdrawal phase, which is mainly characterized by all typical withdrawal symptoms, is probably naltrexone-induced and can be seen in most patients as group A symptoms during the whole day 1, and as group B symptoms on the morning of day 1. In a second phase, concerning fewer patients and extending between the end of day 2 and the morning of day 3, aches, insomnia, and loss of appetite worsened, which can be interpreted as being related to the further significantly declining methadone concentrations.
Group B symptoms, mainly related to neurovegetative hyperactivation and characterized by a high initial prevalence and rapid disappearance, could be related to the antagonistic effects of naltrexone which disappeared from day 2 onwards due to the short half-life of naltrexone and the reappearing effect of the remaining methadone concentrations.
Group D symptoms, muscle twitches, insomnia and lack of appetite, which reappeared in some patients at the end of day 2 and the beginning of day 3, could be interpreted as being related to the falling methadone plasma levels, as their beginning coincides with the habitually expected beginning of most of the methadone withdrawal symptoms. In those patients who complained about muscle twitches and pain, insomnia the night before seemed to be a premonitory sign. Therefore, the present treatment procedure seems to shorten the course of some typical opiate withdrawal symptoms, to move forward and at the same time shorten the neurovegetative hyperactivation associated with withdrawal, and therefore represents a promising alternative as a methadone detoxification method. A significant problem remains the reappearance of some distressing symptoms on day 3, which can be counteracted with adequate analgesic co-medications in future treatment protocols, for instance with ibuprofen.
The results of this study need to be viewed against their methodological limitations. The recorded differences between the symptom groups could have been due to observation biases, as the group B symptoms such as tremor are easily recognizable phenomena or likely to be reported by the patient such as nausea, whereas group C symptoms such as yawning, lacrimation, and rhinorrhea rely completely on the observation skills of the monitoring nurse. Further evident limitations of this pilot study are the open treatment conditions, the limited sample size, the limited observation duration, and the non-standardized followup, and the lack of biological validation (e.g. urinanalysis) of drug use during the follow-up period.
In conclusion, a short detoxification procedure using a single naltrexone dose appears to be a feasible alternative method for methadone detoxification, and seems to accelerate and shorten the withdrawal-associated symptomatology.
